Rafael Holdings, Inc.(RFL)
USD --+0.00%
Reward51Moderate
Risk52Moderate
📊75%Data
Revenue growing 88% YoY
RFL
+0.0 · +0.00%
USD · NYSE
Rafael Holdings, Inc. | Real Estate
Profitless Growth
Market Cap:65.74M
ℹ️
Reward Rating
51
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
52
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RFL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Rafael Holdings, Inc.?

primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

RFL · Verdict

Moderate reward · elevated risk

RFL stands out on balance sheet and volatility, but watch the cash flow signal.

Based on 88% data coverage

RFL · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet76/100

    Current ratio 4.89

  • Volatility65/100

    Above average

Watchouts 2

  • Cash flow12/100

    -2064% free-cash-flow margin

  • Profitability28/100

    -3328% net margin · -38% ROE

Model-based scoring. For information only — not financial advice.

What is Rafael Holdings, Inc.?

primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company is listed on the NYSE in USA, operating in the Real Estate sector, with a market capitalisation of 65.74M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Performance tied to macro conditions — sensitive to interest rate cycles.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorReal Estate
Market Cap65.74M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.19
52 Week Low1.12
Last AnnualJuly
IPO Date3/26/2018
IncorporatedUSA
Shares Outstanding51M
No. of Employees21
IndustryReal Estate Services
ExchangeNYSE
Beta0.601
CurrencyUSD